Clinical Trial Update: Lapatinib (GW572016) for Metastatic or Recurrent Squamous Cell Carcinoma Esophagus [Phase 2]

View source ↗

Summary

A Phase 2 trial of lapatinib for metastatic or recurrent esophageal squamous cell carcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Lapatinib (Lapatinib)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Metastatic or Recurrent Squamous Cell Carcinoma of the Esophagus | Phase 2 | Status: TERMINATED